CJC-1295
Also referred to as: Modified GRF (1-29), DAC:GRF
A lab-made copy of a natural growth-hormone signal, designed to last longer in the body. Studied mostly in early lab research.
In plain terms: CJC-1295 is a lab-made version of the natural signal that tells the body to release growth hormone, tweaked to stick around longer. Most of the research on it is early-stage lab and animal work, not human trials.
- Name
- CJC-1295
- Aliases
- Modified GRF (1-29), DAC:GRF
- Classification
- GHRH analog (peptide)
- Areas studied
- GHRH signaling, Growth-hormone axis, Peptide half-life
What it is
CJC-1295 is a lab-made peptide based on a piece of the natural growth-hormone-releasing signal (GHRH). Like the natural signal, it tells the pituitary gland to release growth hormone. What stands out in the research is that its structure is changed to make it last much longer in the body than the natural version.
Research on CJC-1295 is mostly early-stage lab and animal work.
Mechanism
Like other peptides in its group, CJC-1295 plugs into the GHRH docking point on the pituitary gland to prompt growth-hormone release. Some versions include a special modification (called DAC) studied for how it stretches out how long the peptide stays active in the blood.
The growth-hormone-to-IGF-1 chain is the downstream system researchers are interested in here.
Areas studied & investigated
The categories below summarize where CJC-1295 appears in the research literature. They describe what the compound is studied for and investigated in — not approved uses, and not guidance for any kind of use.
Growth-hormone signal
Studied as a signal that prompts the pituitary to release growth hormone.
Long-lasting design
A go-to example of chemistry used to make a peptide last longer in the body (the DAC modification).
Growth hormone & IGF-1
Looked at for effects on growth hormone and the IGF-1 it drives, in lab models.
Comparing similar peptides
Often compared with other growth-hormone-signal peptides in research.
Research history
CJC-1295 was developed as part of research into longer-lasting growth-hormone signals, with early studies describing how it behaves. It comes up often when researchers compare peptides in this group.
State of the literature
The research on CJC-1295 is mainly early-stage and lab-based. It is not an approved drug.
What to keep in mind
CJC-1295 has much less research behind it than its popularity might suggest, and almost none in people. "Designed to last longer" is a chemistry feature, not evidence that it is safe or does anything useful in humans. Be especially cautious with confident online claims here — the published research simply does not go that far.
Research tools
Evaluating a CJC-1295 batch for laboratory research? These free, research-use-only calculators help you work the numbers and read the paperwork: the reconstitution calculator solves vial concentration and draw volume, and the COA reader walks a certificate line by line. For how much and how often CJC-1295 is commonly used, see the dosing guides.
Batch-tested with published COAs
See what a published COA looks like
Midwest Compounds does not currently list CJC-1295. Every compound it does sell is tested by an independent lab, with a batch-linked certificate of analysis you can check before you buy.
Citations
The summary above is drawn from published, peer-reviewed sources. Links open the abstract on PubMed, or the free full text on PubMed Central (PMC) where marked.
- Teichman SL, et al. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone. Journal of Clinical Endocrinology & Metabolism, 2006. Abstract
- Ionescu M, Frohman LA. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. Journal of Clinical Endocrinology & Metabolism, 2006. Abstract